SEC Form 4 · accession 0000899243-15-007138

BIOGEN INC. · BIIB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 22, 2015

Accepted (ET)

Oct 26, 2015 · 7:03 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875045

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F3,F4	Oct 22, 2015	P	210,000	$277.80	A	210,000	I	See Footnotes
Common Stock^F2,F3,F4	Oct 23, 2015	P	100,000	$276.77	A	310,000	I	See Footnotes
Common Stock	holding	—	—		—	7,890	D

No Table II lines on this filing.

F1On October 22, 2015, each of Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic") and Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership ("Sarissa Offshore"), purchased an aggregate of 128,806 and 81,194 shares, respectively, of common stock of Biogen Inc.
F2On October 23, 2015, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 61,336 and 38,664 shares, respectively, of common stock of Biogen Inc.
F3Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds. Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own.
F4Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein.